Licensing Opportunity
PolyTherics Ltd has developed new pegylation technology for extending the life of protein drugs and improving their properties. The company is now looking for partnerships with biopharmaceutical product-focused companies for the exploitation of its new technologies.
The company says the development enables the targeted, controlled pegylation of practically any recombinant protein. CEO Keith Powell will describe the advances at the BIO-Europe Conference, being held in Dusseldorf, Germany next week (November 17 – 19).
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
